Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Crossover Study to Determine the Intra-subject Variability of the Pharmacokinetics of Single Oral Capsule Dose of 20 mg Lomitapide in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Phase 1, Open-label, Crossover Study to Determine the Intra-subject Variability of the Pharmacokinetics of Single Oral Capsule Dose of 20 mg Lomitapide in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Mar 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lomitapide (Primary)
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type I; Hyperlipoproteinaemia type II
  • Focus Pharmacokinetics
  • Sponsors Aegerion Pharmaceuticals

    • Most Recent Events

    • 26 Mar 2014 Status changed from recruiting to completed European Clinical Trials Database.
    • 26 Oct 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2013-002692-17).
    • 08 Aug 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top